In this randomized trial of more than 9300 subjects with T2DM and high cardiovascular risk, liraglutide was seen to decrease the incidence of the composite cardiovascular primary endpoint (occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) compared with placebo (13.0 and 14.9% in the liraglutide and placebo group, respectively
Huang CC, Tien YJ, Chen MJ, Chen CH, Ho HN, Yang YS
Regrettably, my expectations did not align with the outcomes
doi: 10.1152/ajpregu.1989.256.1.R276 40 Al SabieFTariqZEricksonDDoneganD
Masi, A., Glozier, N., Dale, R
When free radical production outpaces the body's antioxidant defenses a state known as oxidative stress cells accumulate damage that affects energy, immunity, skin health, and accelerates biological aging